Reuters logo
BRIEF-Allergan settles Restasisn 0.05% patent litigation with Famy Care
2017年8月28日 / 晚上8点19分 / 3 个月前

BRIEF-Allergan settles Restasisn 0.05% patent litigation with Famy Care

Aug 28 (Reuters) - Allergan Plc

* Allergan announces settlement of Restasis (Cyclosporine Ophthalmic Emulsion) 0.05% patent litigation with Famy Care

* Allergan PLC - ‍Agreement provides dismissal of litigation and termination of pending IPR petitions​

* Allergan PLC says additional details regarding settlement were not disclosed

* Allergan PLC - ‍As a result of settlement, all Famy Care litigation regarding Restasis patents will be dismissed​

* Allergan PLC - ‍As a result of settlement, Famy Care will terminate its pending petitions for inter parties review​

* Allergan - Co will grant Famy Care license to market generic version of Restasis in U.S. beginning Feb 27, 2024, or earlier under some circumstances​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below